| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8527906 | Clinical Therapeutics | 2018 | 18 Pages |
Abstract
Due to the high price of daratumumab, neither the addition of daratumumab to Rd nor Vd proved to be cost-effective under US WTP. However, if the daratumumab price fell to a certain discount level, the DVd regimen might be cost-effective.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Tian-tian PhD, Sen MS, Ning PhD, Li MD, Zugui PhD, Jie PhD,